Valuation: Adimmune Corporation

Market Cap 6.98B 216M 188M 175M 160M 303M 20.62B 308M 2.06B 809M 10.27B 811M 793M 34.42B P/E 2024
-34.7x
P/E 2025 -33.2x
Enterprise Value 7.59B 235M 204M 190M 175M 330M 22.43B 335M 2.24B 880M 11.17B 882M 863M 37.45B EV / Sales 2024
5.53x
EV / Sales 2025 6.14x
Free-Float
70.19%
Yield 2024 *
-
Yield 2025 -
1 week-2.93%
1 month-5.97%
3 months-6.50%
6 months-13.12%
Current year-12.66%
1 week 16.4
Extreme 16.4
17.55
1 month 16.4
Extreme 16.4
18.2
Current year 16.4
Extreme 16.4
21.5
1 year 16.4
Extreme 16.4
22.5
3 years 15.9
Extreme 15.9
36.6
5 years 15.9
Extreme 15.9
56.2
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 20/06/2019
Director of Finance/CFO - 01/01/2021
Chief Tech/Sci/R&D Officer - 26/01/2022
Director TitleAgeSince
Director/Board Member - 20/06/2019
Director/Board Member - 15/08/2011
Director/Board Member - 29/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-2.93%-3.78%-52.78% 216M
+3.29%+16.25%+39.81%+2.79% 76.15B
-2.75%+48.50%+48.50%+48.50% 47.83B
+2.72%-9.39%+17.04%+176.83% 48.89B
-3.81%+7.74%-54.57%-54.17% 41.37B
-2.40%+0.38%+58.55%-24.89% 29.99B
-2.82%+1.57%+59.59%+87.57% 24.23B
-5.35%+1.39%+85.45%-53.41% 21.75B
-1.59%-3.61%-11.53%+150.58% 19.25B
-0.42%+2.89%+74.55%+128.45% 17.14B
Average -1.69%+1.01%+31.36%+40.95% 32.68B
Weighted average by Cap. -1.49%+2.97%+30.72%+43.57%

Financials

2024 2025
Net sales 1.56B 48.21M 41.91M 39.01M 35.82M 67.64M 4.6B 68.69M 460M 180M 2.29B 181M 177M 7.68B 1.4B 43.4M 37.73M 35.12M 32.24M 60.88M 4.14B 61.83M 414M 162M 2.06B 163M 159M 6.92B
Net income -243M -7.52M -6.53M -6.08M -5.58M -10.55M -718M -10.71M -71.69M -28.14M -357M -28.23M -27.61M -1.2B -240M -7.43M -6.46M -6.01M -5.52M -10.42M -709M -10.58M -70.85M -27.81M -353M -27.9M -27.29M -1.18B
Net Debt 140M 4.32M 3.76M 3.5M 3.21M 6.06M 413M 6.16M 41.22M 16.18M 205M 16.23M 15.87M 689M 612M 18.96M 16.48M 15.34M 14.09M 26.6M 1.81B 27.01M 181M 70.97M 901M 71.21M 69.64M 3.02B
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
31/07/26 NT$16.55 -.--% 1,058,937
30/07/26 NT$16.55 -0.30% 1,133,052
29/07/26 NT$16.60 -0.90% 2,312,248
28/07/26 NT$16.75 -2.05% 1,394,863
27/07/26 NT$17.10 +0.29% 992,771
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4142 Stock